Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Ofotokun, Ighovwerha ^a   Chuck, Susan K ^b   Schmotzer, Brian ^c   O'Neil, Kelly L ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; GEL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TABLET; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78650478166     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-29     Document Type: Article

References (15)

1. Kaletra US Prescribing Information. 2007, Abbott Laboratories, North Chicago, IL 60064 USA, Accessed October 28, 2009., http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021251s026,021906s017lbl.pdf
2. Klein CE, Chiu YI, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. Journal of Acquired Immune Deficiency Syndromes 2007, 44(4):401-410. 10.1097/QAI.0b013e31803133c5, 17224848.
3. Awni W, Chiu YL, Zhu T, et al. Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation. Abstract WeOa0206. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment 2005, Rio de Janeiro, Brazil.
4. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-46. 10.1056/NEJMoa012354, 12087139.
5. Johnson M, Grinszstein B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005, 19:685-694. 10.1097/01.aids.0000166091.39317.99, 15821394.
6. Department of Human Health Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Accessed October 28, 2009., http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
7. Gathe J, Silva BA, Cohen DE, et al. A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks. J Acquir Immune Defic Syndr 2009, 50:474-81. 10.1097/QAI.0b013e31819c2937, 19225400.
8. Sherman DS, Fish DN. Management of Protease Inhibitor-Associated Diarrhea. Clin Infect Dis 2000, 30:908-914. 10.1086/313826, 10854364.
9. Bongiovanni M, Bini T, Chiesa E, et al. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res 2004, 62:53-56. 10.1016/j.antiviral.2003.12.002, 15026202.
10. Schrader S, Chuck SK, Rahn LW, et al. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Research and Therapy 2008, 5:21. 10.1186/1742-6405-5-21, 2563011, 18799008.
11. Gathe JC, Lipman BA, Mayberry C, et al. Tolerability and therapy preference of lopinavir/ritonavir (Kaletra®) soft-gel capsules and tablets as single agent in a cohort of HIV positive adult patients (IMANI-2). Poster number P62. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK 2006,
12. Rawlings MK, McGhee TA, Casey-Bailey S, et al. Tolerability and preference of lopinavir/ritonavir (Kaletra) capsules versus tablets in an African American cohort. American Conference for the Treatment of HIV. Dallas, TX 2007,
13. Shahriar J, Delate T, Hays RD, et al. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health and Quality of Life Outcomes 2003, 1:-25. 10.1186/1477-7525-1-25, 183842, 12914664.
14. Sprinz E, Neto JA, Bargman E, et al. Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy. HIV Clinical Trials 2006, 7:291-308. 10.1310/hct0706-291, 17197377.
15. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977, 1:385-401.